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During the past  two decades, dengue viruses have been a  major cause of 
severe illness and death among children in tropical Asia (1). Dengue viruses are 
mosquito-borne flaviviruses which occur as four antigenically distinct types. 
Homotypic immunity is thought to be life long, but after a brief period of cross- 
protection, heterotypic infections occur and are accompanied by secondary-type 
antibody responses (2, 3). Severe dengue, the shock syndrome (DSS), 1  is charac- 
terized by abnormalities of hemostasis, and hypovolemic shock (4-7). Studies in 
Thailand have documented a  significant correlation between disease severity 
and the immune status of the host before infection. The risk of shock is greater 
during secondary compared with primary dengue infections (6, 8, 9). In a large 
experience, more than 95% of shock cases over the age of 1-yr had secondary- 
type dengue antibody responses (4, 6). DSS and the milder, but pathogenetically 
similar dengue hemorrhagic fever without shock also occur frequently in infants 
in dengue endemic areas (8). Usually these infections are of the primary type 
(6). In a few instances the mothers of such infants have been studied and all 
have had dengue antibodies presumably from infections which antedated preg- 
nancy (7,  10). From these and similar observations it was hypothesized that 
severe dengue illness is the result of a hypersensitivity phenomenon, pre-illness 
antibody "sensitizing" individuals to subsequent dengue infection (11). 
Clinical and experimental studies on humans and monkeys have provided 
data  from  which  were  developed new  and  provocative  concepts  of possible 
immunopathologic mechanisms resulting in vascular permeability and hemor- 
rhage in dengue infection. Several groups of workers have shown that during 
the shock stage of dengue, complement (C) is activated, in some instances by 
both the alternate and classical pathways (7, 10). In the heterologously immune 
host, virus replication occurs in the presence of cross-reacting antibody. Under 
these conditions large amounts of C-fixing virus-anti-dengue IgG complexes 
should be produced. In this model, it has been predicted that vascular permea- 
bility is mediated by histamine released by immune complex-activated  peptides, 
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C3a and C5a (12).  This hypothesis does not satisfactorily explain how C deple- 
tion  and  shock  can  occur  in  8-  or  9-mo-old  infants  who  presumably  have 
extremely small amounts of residual maternal  anti-dengue IgG. 
We believe that antibody contributes to the severity of dengue infection by an 
entirely  different  mechanism,  by regulating  the  infection  of cells  (13).  This 
phenomenon,  immunological  enhancement  of dengue  infection,  has  been ob- 
served in experimentally infected monkeys and in cultures of primate  periph- 
eral blood leukocytes (PBL). Monkeys monotypically immune to dengue viruses 
types 1, 3, or 4, when infected with dengue type 2 (D2V), circulated more virus 
than did nonimmune animals infected with the same virus strain administered 
by the same route and at the same dose (14). Similarly, PBL cultures prepared 
from dengue-immune monkeys or human beings readily supported dengue virus 
(D) replication while leukocyte cultures from non-immunes were not permissive 
(15-17).  Recently,  we have  published preliminary  evidence that  non-neutral- 
izing dengue antibody when added to PBL cultures from nonimmune primates 
results in productive infections similar to those occurring in cultures of immune 
PBL (18).  The relevance of these observations are reinforced by virus recovery 
studies on dengue-infected human beings and monkeys which strongly suggest 
that leukocytes are the predominant or the only sites of D replication (19, 20). 
This  and  the  companion  paper  present  further  data  on  in  vitro  antibody- 
mediated  enhancement  of dengue  infection  in  primate  leukocytes  (21).  We 
report studies on the effect on viral replication of different methods of separating 
and culturing leukocytes, the kinetics of viral replication, the kinetics of inter- 
nalization of virus, the immunoglobulin which mediates infection enhancement, 
the nature of the leukocyte antibody-binding site,  and the attributes  of virus- 
antibody-leukocyte interactions. Separately, we describe studies on the identifi- 
cation of blood and tissue leukocytes which support antibody-mediated dengue 
infection (21). 
Materials  and  Methods 
Virus Preparations and Assays.  D types 1 (strain 16007),  2 (strain 16681),  3 (strain 16562), and 
4 (strain 4328 S) were propagated either in continuous rhesus (LLC-MK2) or vervet (Vero) monkey 
kidney cells for 4-6 days in basal medium Eagle's (BME), with Earle's salt solution and 10% calf 
serum. Infected cells were disrupted by freeze-thawing and the suspension clarified by centrifuga- 
tion at 2,000g for 15 min. Virus in supernatant fluid was then concentrated by ultracentrifugation 
in a  10  ×  10 angle head rotor either in a  Spinco L-65 (Beckman Instruments, Inc.,  Spinco Div., 
Fullerton, Calif.) or MSE Superspeed 65 (MSE Scientific Equipment, Crawley, Sussex, England) 
at 100,000 g  for 60 min. The pellet and the lowest 10% of the supernatant fluid were retained and 
resuspended by brief sonication. Fetal bovine serum (FBS), or agamma calf serum was added to a 
final concentration of 20-50% and the virus suspension stored at  -70°C in multiple vials. Virus 
was quantitated by a  plaque method in LLC-MK2 cells (22),  or PS cells (23).  For both systems, 
leukocyte suspensions were diluted 1:10 and the assay vol was 0.2 ml. For LLC-MK2 cells, inocula 
were added to each of three 1 ounce prescription bottles containing cell monolayers for 90 rain at 
37°C and then overlaid with Noble agar containing BME, 100% calf serum, and neutral red. The 
bottles were incubated in the dark for 7 days at 37°C,  then for 7 days at room temperature and the 
plaques counted. In the PS cell assay, virus inoculum was added to cells to produce a total vol of 0.4 
ml at a cell concentration of 1.5 ×  105 cells/ml. After 4 h incubation of virus with cell suspension at 
37°C,  an overlay (0.4 ml) was added consisting of a  final concentration of 1.5% carboxy methyl- 
cellulose (sodium salt; British Drug Houses, Ltd., London, England) supplemented with 3% FBS 
(GIBCO  Bio-Cult,  Ltd.,  Paisley,  Scotland),  L-glutamine,  antibiotics,  and  with  10%  tryptose 
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replicate  16-ram  diameter  wells  in  plastic  Disposo Trays (Model  FB16-24TC; Linbro  Chemical  Co., 
New Haven, Conn.). After 96-108 h at 37°C the overlay medium was removed, cells  rinsed in 
saline,  and  stained  with  a naphthalene  black-acetic  acid  solution.  PS cell  concentrations  required 
to  form  dense  monolayers  were  found  to  vary  with  different  cell  lots  betwen  1.5  and  3.0  × 105/ml.  In 
some instances  it  proved  necessary to  increase  the  volume of  L-15 medium and overlay to  provide 
sufficient  nutrients  to maintain healthy  cells  throughout  the 5-day incubation period. 
Replicate plaque assays of individual samples are shown as mean values -+ one standard 
deviation;  grouped data from several samples are shown as means _+ one standard error  of  the 
mean. Differences  between mean values were tested  by Student's  t  test  for  paired data using  the 
square roots  of  plaque counts. 
Antibody Production.  Dengue antibodies were either obtained from naturally infected human 
beings or raised in rhesus monkeys or mice which were without neutralizing antibody to dengue 
types 1-4. Monkeys were infected by a single subcutaneous inoculation of approximately 1 × 104 to 
1 × 10  s plaque-forming units (PFU) of  tissue culture passaged dengue viruses. Some animals were 
bled at intervals of 2-3 days for the first 2 wk after inoculation and then at 3 and 6 wk. For routine 
preparation of monkey anti-dengue, animals were bled at least 2 mo after a single inoculation. In 
mice,  antibodies were raised by the immunization schedule of Brandt  et al.  (24) using saline 
suspensions of homogenized mouse brains infected with prototype mouse passaged dengue viruses. 
Antibodies were obtained in ascitic fluids induced by sarcoma 180 cells (25). 
Antibody Measurement.  Antibodies were measured by the hemagglutination-inhibition (HI) 
test and the plaque reduction neutralization test (PRNT).  The HI test was performed in Microtiter 
plates  (Cooke  Laboratory Products  Div., Dynatech  Laboratories,  Inc.,  Alexandria, Va.)  using 
microvolumes and standard methods (26). All serum or plasma samples were treated with kaolin 
(Flow Laboratories,  Inc.,  Rockville, Md.)  to  remove nonspecific hemagglutination inhibitors. 
Goose erythrocytes and eight antigen units were used in all tests. The 50% PRNT was performed 
in LLC-MK2 or PS cells using virus assay methods described above.  Virus-serum mixtures were 
incubated for 60 min at 37°C before virus assay. Antibody titers were calculated on log probit paper 
by the method of Russell et al.  (27). 
Separation and Chemical Modification of Antibodies.  Anti-dengue serum was separated into 
different immunoglobulin types by two methods:  (a) density gradient centrifugation. This was 
carried out in a discontinuous sucrose gradient consisting of successive layers of 1.0 ml of 40%, 1.5 
ml of 25%, and 1.0 ml of 10% sucrose in a phosphate buffer, pH 7.4. After overnight incubation at 
4°C, 0.4 ml of a 1:2 dilution of serum was layered on a 4,5 ml gradient and centrifuged in a 3 x 5 ml 
swing-out head (MSE Scientific Equipment) in a MSE Superspeed 65 ultracentrifuge at 35,000 rpm 
(100,000 g) for 18 h. Fractions of 0.5 ml were collected by piercing the bottom of the lusteroid tube. 
These were dialyzed against borate saline, pH 9.0. Fractions collected from the upper one half of 
the tube were treated with kaolin before measuring HI antibody.  (b) DEAE-cellulose chromatog- 
raphy.  Gamma globulins, precipitated twice by 33% saturated ammonium sulfate, were exhaus- 
tively dialyzed against 0.01 M phosphate buffer, pH 7.8, and then applied to a  DEAE-cellulose 
column. The IgG fraction was obtained by pooling the first protein peak eluted by 0.01 M PO4 
buffer, pH 7.8, and concentrated to 10 mg/ml on an Amicon ultrafiltration unit (PM10 membrane; 
Amicon  Corp.,  Lexington,  Mass.).  The  IgG sample  was  further  purified  by  Sephadex  G-200 
chromatography. 
F(ab)~ fragment was prepared from IgG by pepsin digestion (pepsin  P 7012; Sigma Chemical 
Co., St. Louis, Mo.) at a 1:50 ratio of pepsin to sample by published methods (28) and separated by 
Sephadex G-200 gel filtration (Pharmacia Fine Chemicals Ltd.,  Uppsala, Sweden).  The protein 
content of purified IgG and F(ab)2 was measured by the Lowry method (29). The dengue antibody 
activity of each immunoglobulin preparation was measured by the HI test using dengue 2 antigen 
and PRNT vs. D2V. 
The specificity and purity of separated immunoglobulins was tested by immunoelectropboresis 
and Ouchterlony using goat anti-human (anti-7 ~, a, K, k) IgG and IgM (Nordic Diagnostics, Sera 
Service Limited, Maidenhead, Berkshire, England), and quantitated by radial immunoprecipita- 
tion using reagents prepared and standardized  by the Immunology Division, Northwick Park- 
Clinical Research Centre,  London.  The purity of F(ab)2 was determined by Ouchterlony using 
anti-human IgG, anti-F(ab), and anti-Fc serums (Nordic Diagnostics Sera Service Limited). 
Leukocyte  Separation  and Culture.  Blood  was anti-coagulated either in heparin,  20  IU/ml 
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citrate-phosphate-dextrose  (CPD) solution, 63 ml in 450 ml blood, each 100 ml contained sodium 
citrate, 2.65 g; dextrose, 2.32 g; citric acid, 327 mg; and sodium acid phosphate,  251 mg (Fenwal 
Division, Travenol Laboratories,  Ltd.,  Thetford,  Norfolk, England),  in dipotassium EDTA at a 
final concentration  of 1.5  mg/ml  (Stayne,  London,  England)  or defibrinated  using three  glass 
beads in 20 ml blood. Leukocytes were recovered either by dextran sedimentation or by adding 
blood to 2 volumes of 2.4% dextran T-250 (Pharmacia Fine Chemicals Ltd.), incubating at 37°C for 
30 min, and removing the leukocyte-rich plasma with a pipet, or by the density flotation method 
(30)  in which anti-coagulated  blood was diluted  approximately 1:3 in phosphate-buffered saline 
without Ca  ++ or  Mg  ÷+ (PBSA) and underlayed  with a Ficoll-Triosil  (Hypaque) solution  prepared 
as  described  by B~iyum (30)  (Ficoll;  Pharmacia Fine Chemicals Ltd.,  and  Triosil  440;  Nyegaard & 
Co.,  AS, Oslo).  Mononuclear leukocytes were separated centrifugally  at  400  g, and washed three 
times in  PBSA, suspended in Hanks'-buffered salt  solution  (HBSS), counted, and  resuspended at 
1.5  or  1.0 × 10  e  cells/ml  in  RPMI 1640 (GIBCO Bio-Cult,  Ltd.)  with  20  mM  Hepes  buffer  and  0.02% 
sodium bicarbonate and 10% heat-inactivated  FBS (complete RPMI). Leukocytes  were incubated 
for  up  to  7  days  without  change  of  medium in  stoppered  or  capped  plastic  or  glass  vials  or  tubes. 
Infection of Leukocytes.  Specific conditions for infection of PBL are described under Results. 
Three  large  lots  of D2V  were  used.  During  the  first  2  yr  of the  study,  residual  virus  from 
experimental use was always assayed.  When this experience showed that D2V viability in large 
seed lots was stable, in subsequent experiments, lots were titered at monthly intervals. Approxi- 
mately one-half of the experiments described in this study utilized a  single lot of monkey anti- 
dengue 4 serum (aD4), H-187, at a  1:200 final dilution. 
Treatment  of Leukocytes with Proteolytic Enzyme.  Separated and washed human and monkey 
PBL were suspended at 1  ×  107 cells/ml in PBS, pH 7.8,  containing 0.02%  EDTA, following the 
methods of Kedar et al.  (31). To each milliliter of PBL suspension was added an equal volume of 
serially 10-fold  diluted trypsin  (bovine pancreas type III, twice crystallized, 12,500  BAEE U/mg 
protein; Sigma Chemical Co.).  Mixtures were placed in a  37°C water bath and shaken intermit- 
tently for 30 min. Cells were washed three times in HBSS, counted, resuspended to 1.5  ×  10e/ml, 
and either D2V only or D2V plus aD4 added. 
In other experiments,  PBL were treated in similar fashion with twice crystallized papain,  17 
uts/mg  protein  (Sigma  Chemical Co.),  and  pronase,  B-grade 45,000  PUK/g  (Calbiochem,  San 
Diego, Calif.). 
Results 
Effect of Methodological  Variables on Infection 
ANTI-COAGULANT.  Heparin  sodium,  with or without preservative,  was the 
anti-coagulant  employed in initial experiments.  In the whole series,  158 blood 
samples were anti-coagulated with heparin before attempts to study antibody- 
enhanced D2V replication in monkey or human PBL. Viral replication exceeded 
50 plaque-forming  units  (PFU) per  106 mononuclear  PBL in  123 of these cul- 
tures. In an attempt to simplify blood collection, 11 human blood samples were 
defibrinated.  D2V replication was observed in only three of these experiments. 
After  this  experience,  the  effect  of anti-coagulant  on  D2V  replication  was 
compared in three experiments.  Blood from human donors was defibrinated or 
anti-coagulated with heparin,  CPD, or EDTA. Leukocytes were then separated 
by  Ficoll-Hypaque,  counted,  suspended  at  1  ×  106  mononuclear  PBL/ml  in 
RPMI-1640 with 10% heat-inactivated calf serum, and D2V added at a multiplic- 
ity of infection (MOI) of 0.01 together with a  1:200 final concentration of H-187 
aD4.  Cells were assayed on days 1-4. No significant difference in virus produc- 
tion was observed on any day in cultures prepared from blood anti-coagulated 
with heparin,  CPD, or EDTA. No viral replication was observed in two of three 
defribinated samples. In the third sample viral replication occurred at high titer 
in cells separated by each method. 
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D2V replication was compared directly only two times. In approximately one- 
half  of 158 experiments, PBL were separated from erythrocytes using dextran T- 
250, in the other half, PBL were separated on Ficoll-Hypaque. The average PFU 
per milliliter culture medium on days 1-4 did not differ with separation tech- 
nique. In 10 experiments virus replicated well in whole blood anti-coagulated 
with heparin and diluted 1:5  in RPMI-1640 with 10%  FBS or 10%  autologous 
serum. 
CULTURE MEDIA.  Using RPMI-1640  medium in  stoppered  culture vessels, 
D2V  yield was  optimal  when  pH  was  regulated  with  20  mM  Hepes  buffer 
together with 0.02% sodium bicarbonate. Gassing cultures with 5% CO2 in air 
did not affect viral replication when compared with ungassed cultures. Satisfac- 
tory virus yields were also obtained in five experiments in which PBL were 
cultured in M-199  with 5% or  10%  FBS plus 2%  sodium bicarbonate.  In four 
experiments,  human  PBL  cultured  in  L-15  medium  with  10%  FBS  did  not 
support D2V synthesis, while virus replicated normally in control cells main- 
tained in RPMI-1640. 
Interactions  between Leukocytes,  Virus, and Antibody 
KINETICS OF VIRUS REPLICATION.  There was considerable variability in the 
amount of  D2V replicated and the day of  peak infection in primate PBL cultures. 
Even  when  PBL  concentrations were  standardized,  D2V  added at  a  narrow 
range of MOI (0.1-0.01)  and one lot of aD4 used at a single final dilution, large 
differences in virus growth were observed. Six illustrative D2V growth curves in 
PBL cultures with and without antibody are shown in Fig.  1.  In some cases 
(exps.  I  and II) viral replication occurred only in PBL cultures supplemented 
with antibody; in other instances, D2V growth in cultures with antibody showed 
only transient differences from control (exp.  III) or no difference from control 
(exp. IV); in some experiments, the late production of D2V was observed in PBL 
cultures without antibody. Virus  replicated was either significant, less than 
D2V grown in antibody-containing cultures (exp. V),  or less often, differences 
were not significant (exp. VI). 
In  112/145 paired  experiments  a  significant difference in  D2V  replication 
between cultures with antibody compared to those without was observed on at 
least 1 day of culture. Because of the variation in day of peak virus production, 
virus assay results for 2 or more days were generally pooled. For monkeys this 
usually included clays 3-5;  for humans,  days 2-4.  This evaluative procedure 
resulted in large standard deviations and standard errors of the mean. 
Similar variations in the replicative kinetics of D2V were observed in human 
PBL cultures. Paired data in Fig. 2 were obtained from PBL cultures prepared 
from the same donor over a period of 9 mo. A single batch of virus and aD4 were 
used. 
ANTIBODY  SPECIFICITY,  IMMUNIZATION  METHOD,  AND  SPECIES  OF  ANTIBODY 
DONOR.  D2V infection enhancement in monkey or human PBL was produced 
by antisera raised to dengue types 1, 3, and 4 viruses using several species as 
antibody donors.  We have tested one or more lots of anti-dengue raised in 10 
monkeys, anti-D1 (2), anti-D3 (2), anti-D4 (6), 2 pools each of anti-D1, 3, and 4 
mouse  immune  ascitic  fluids,  single  rabbit  antisera  to  each  of these  three 
viruses, and serums from five monotypic dengue-immune human beings. All of 206 
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Fro.  I.  (a, b, and c) Variability  of antibody-enhanced  D2V  replication in six selected 
rhesus PBL  cultures  (exps. I-VI). PBL  cultures  were prepared at different times from 
monkey H-190 over a period of  5 too.  To each was added the same lot  of  D2V at a MOI of  0.1 
and one half  of  each suspension received a 1:10  final  concentration of  rhesus H-30 aD4 (Ab). 
Cultures containing D2V only serve as control (C). After 120 rain PBL were washed three 
times, counted, resuspended to 1.5 x l(~/ml, cultured days 1-6,  and freeze-thawed suspen- 
sions assayed. Virus titers  were standardized to 1 x  10  e  PBL. 
these serums produced infection enhancement  at or  above  1:10 final dilutions. 
Representative  results  obtained from testing five serums  simultaneously  are 
shown  in  Fig.  3.  Heterotypic  anti-dengue  serums  had  only  low-titered  50% 
plaque reduction  activity against  D2V.  From experimental  results  not shown 
the  amplitude  of enhancement  and enhancing  titers was shown to vary with 
individual sera and not with anti-dengue specificity. S.  B.  HALSTEAD  AND  E.  J.  O~ROURKE  207 
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FzG.  2.  Mean D2V titers on days 2-5 in five human PBL cultures incubated with and 
without  H-187 aD4.  Cultures  prepared over a  period of 9  mo from a  single nonimmune 
donor. Paired results are shown in closed (with antibody) and open (no antibody) symbols. 
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FIG.  3.  Fold increase in D2V replication in human PBL cultures at varying dilutions of 
dengue antisera. Dengue 2 plaque reduction neutralization titers of tested sera: mouse anti- 
dengue 1, 1:15; rabbit anti-dengue 2, 1:320; rabbit anti-dengue 3, 1:40; monkey (H-187) anti- 
dengue 4,  1:20; human (SBH) anti-dengue 1-4,  1:717. 
Homotypic anti-dengue  2 enhanced  D2V replication  at dilutions  above neu- 
tralizing end points. A typical result is illustrated in Fig. 3; rabbit anti-dengue 2 
with a 50% PRNT of 1:320 produced significant enhancement beginning at this 
dilution through 1:5,120.  One anti-dengue 2 serum prepared in a rhesus monkey 
with a  homologous PRNT~o of 1:640 had an enhancement titer of 1:320,000. 
ANTI-DENGUE CYTOPHILIA.  Anti-dengue  cytophilia for monkey and human 
PBL were studied in three experiments. Representative results from one experi- 208  DENGUE  AND  MONOCYTES.  I 
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ment in monkey PBL are shown (Fig. 4).  PBL were divided in three portions. 
Anti-dengue 4  was  added to  two  samples,  and  FBS  to  the  third.  Cells  and 
antibody were incubated at 37°C for 120 min and then washed three times. To 
the first portion, D2V plus aD4 were added, and to the second and third D2V 
only. D replication occurred only when aD4 was readded. 
C DEPENDENCE.  No difference in D2V replication was observed in two experi- 
ments in which late convalescent aD4  plus  D2V  was added to monkey PBL 
cultured in  fresh or  heat-inactivated FBS or  autologous nonimmune rhesus 
serum. 
ENHANCING  ACTIVITY OF ANTI-DENGUE IgG  AND  IgM.  Two nonimmune rhe- 
sus monkeys were infected with D2V and bled on days 7,  10,  14, 21, 28, and 45 
after infection. Sera were tested for HI dengue 2 antibodies. The earliest serum 
containing antibody was fractionated on a  sucrose density gradient (Table I). 
After dialysis and without further concentration, fractions were tested for HI 
and neutralizing antibodies and Ig content (Table II). For both animals, frac- 
tions 3 and 7 from day 14 postinfection sera contained uncontaminated IgM and 
IgG,  respectively,  as  ascertained by  immunoelectrophoresis against  anti-Ig, 
anti-IgM, and anti-IgG. Immunoglobulins were quantitated by radial immuno- 
diffusion. By comparing HI antibody titers, in serum and fractions, fraction 3 
represented a 1:10 and 1:20 dilution of rhesus 111 and 112 sera, respectively. The 
concentration of IgG in fraction 7 of rhesus 111 and 112 was approximately 25% 
that of whole serum. D2V infection-enhancing activity was measured in whole 
serum and serum fractions using human PBL (Table III). Titers were expressed 
as  dilution of serum  antibody or IgG.  Whole serum neutralized D2V  at low 
dilutions and gave a weak enhancement at higher dilutions. Anti-dengue IgM 
did not enhance D2V replication at any (serum)  dilution from 1:200 through 
1:102,400. Fraction 7 from both animals had high-titered enhancing activity, but 
FIG.  4.  Failure of aD4 to enhance D2V infection when preincubated with PBL. A 1:10 final 
concentration of heat-inactivated H-130 rhesus aD4 added to first and second PBL suspen- 
sions, and H-190 normal rhesus serum at 1:10 added to the third portion. Sera incubated for 
120 rain at 37°C and removed by washing. D2V (MOI, 0.1) added to all tubes, aD4 replaced in 
first tube. Means from six plaque assays + SE from two replicate experiments are plotted. S.  B.  HALSTEAD  AND  E.  J.  O'ROURKE  209 
TABLe.  I 
Temporal Development of HI and Neutralizing Antibody to D2 V 
After Primary Infection of Two Rhesus Monkeys 
Rhesus 111  Rhesus 112 
Day of infec- 
tion 
Reciprocal titer  Day of infec-  Reciprocal titer 
tion 
HI  PRNTso  HI  PRNTso 
0  <10  <10  0  <10 
7  <10  7  <10 
10  <10  10  10 
14  40  4,800  14  80 
21  40  21  80 
28  40  28  80 
45  40  45  80 
<10 
5,000 
TABLE  II 
Immunoglobulin and Antibody Concentrations in Dialyzed Fractions Collected after 
Centrifugation  of Day 14 Serums on a Sucrose Gradient at 100,000 g for 16 h 
Rhesus 111  Rhesus 112 
Reciprocal titer 
Fraction  IgM  IgG  Fraction  IgM 
HI  PRNTso 
Reciprocal titer 
IgG 
HI  PRNTso 
1 
2 
3 
4 
5 
6 
7 
8 
Whole serum 
mg/lO0 ml*  rag~t00 ml 
0  0  <1  1  0  0  <1 
0  0  1  2  0  0  2 
<25 (+)  0  4  320  3  40  0  4  320 
<25 (+)  0  2  4  +  0  1 
0  +  <1  5  0  +  <1 
0  +  <1  6  0  +  2 
0  305  <1  <10  7  0  481  2  <10 
0  +  <I  8  0  +  <i 
68  1,250  40  4,800  Whole serum  172  1,960  80  5,000 
* Fractions tested by Ouchterlony versus anti-IgM or anti.IgG. Fractions containing the highest 
concentration of IgM or IgG quantitated by radial immunoprecipitation. 
TABLE  III 
D2V Replication  Enhancing Activity in Rhesus Monkey Serums and Sucrose Gradient 
Fractions Obtained 14 Days After Primary Infection 
Rhesus 111  Rhesus 112 
Serum  Fraction 3  Fraction 7  Serum  Fraction 3  Fraction 7 
Dilu-  En-  Dilu-  En-  Dilu-  En-  Dilu-  En-  Dilu-  En-  Dilu-  En- 
hance-  hance  hance-  hance-  tion*  hance  tion#  hance-  tion  tion~  tion* 
tion  ment*  ment  ment  ment  ment  ment 
10  <1  200  <1  40  7.0  10  <1  400  <1  40  8.0 
40  <1  800  <1  160  13.0  40  1.1  1,600  <1  160  12,0 
160  2.9  3,200  <l  640  11.0  160  <1  6,400  <1  640  8.0 
640  1.7  12,800  <1  2,560  4.4  640  1.3  25,600  <1  2,560  5.4 
2,560  2.5  51,200  <1  10,240  2.1  2,560  3.2  102,400  <1  10,240  3.0 
10,240  <1  40,960  <1  10,240  2.3  40,960  <1 
* Day 3 PFU: test sample/control. 
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TABLE  IV 
Immunoglobulin Concentrations,  Anti-D2, and Replication Enhancement Titers in 
Serum, IgG, and F(ab)2 Prepared from a D1.4 Immune Human 
Specimen  Lowry  IgG 
Reciprocal titer 
D2V replication-enhanc- 
ing titer 
HI*  PRNTs0$  Exp. 1  Exp. 2 
mg/lO0 ml rng/lO0 ml 
Serum (SBH)  4,750  1,440  88  -  8  717  25,600  12,800 
IgG (SBH)  170  114  8 -  0  76  1,280  640 
F(ab)~  (SBH)  130  §  5 -+ 0.7  78  <1  <1 
* Mean -+ SD of  i0 replicate  titrations. 
Mean of  two determinations. 
§ Versus anti-human F(ab) = 80 rag/100  ml. 
were without measureable HI or neutralizing activity at the lowest dilutions 
available for test (1:4 serum equivalent). 
Fc DEPENDENCE.  D2V infection-enhancing, HI, and neutralizing activities of 
whole serum and F(ab)2 preparations are shown in Table IV. The ratio between 
enhancing titers in serum and IgG was nearly the same as the ratios of HI and 
neutralizing titers  between  serum  and  IgG.  Although anti-dengue  2  F(ab)2 
possessed both neutralizing and HI antibody to D2V,  the preparation did not 
enhance  D2V  infection.  Similar  results  were  obtained  in both  monkey and 
human PBL. 
PROTEOLYTIC ENZYMES.  Monkey and human PBL were incubated with vary- 
ing concentrations of several proteolytic enzymes for 30 min at 37°C. Enzyme 
was removed by washing, cells incubated with D2V plus aD4 or with D2V alone, 
and viral replication assayed. Heat-inactivated enzyme or no enzyme were used 
as controls. At some dilutions proteolytic enzyme treatment resulted in as much 
as an 18-fold increase in viral replication compared with non-enzyme-treated 
cells (Table V). Infection occurred only in the presence of aD4. Treatment of PBL 
with varying concentrations of enzymes did not increase the permissiveness of 
cells to infection by virus alone (data not shown). Papain and pronase were more 
active than trypsin under the conditions of these experiments. 
PERMISSIVENESS OF  PBL  IN  RELATION  TO  TIME  IN  CULTURE.  Holding leuko- 
cytes in culture before infection was studied as a  possible variable  affecting 
infectibility of cells.  Virus plus antibody or virus only was added to standard 
human PBL cultures shortly after Ficoll-Hypaque separation (time 0) and at 24- 
h  intervals through 96 h. After infection, cultures were assayed on days 1-5. 
Average virus content of PBL cultures on days 2,  3,  and 4 from eight experi- 
ments is shown in Table VI. Virus titer in cells infected after 24 h in culture was 
significantly greater than at other time periods. The 24-h titer differed from that 
at time 0 (P < 0.001). In cells infected at 48 h and later there was sharp decline in 
viral replication. Similar results were obtained in monkey leukocyte cultures. 
KINETICS OF INTERNALIZATION  OF D2V-aD4.  D2V plus aD4 was added to repli- 
cate standardized monkey PBL suspensions and incubated at 37°C. At intervals 
tubes were removed and one half of cells were washed three times,  counted, 
resuspended  at  1  ×  106/ml, incubated,  and  assayed on  days  2-6.  The  other 
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TABLE  V 
D2 V Replication in PBL Treated with Proteolytic Enzymes Before Incubation with D2 V 
Plus aD4 
Trypsin  Papain  Pronase 
Concentration  of  Mean PFU/  Ratio  of  Ratio  of  Ratio  of 
enzyme  10  ~  PBL _  test:con- Mean PFU/10  s test:con- Mean PFU/106  test:con- 
PBL _+ SE  PBL _+ SE  SE*  trois  trol  trol 
mg/ml 
0.0001  476  +_  50  1.0  1760  _+  483  1.1  874  _+  70  1.7 
0.001  509  _+  63  1.1  4566  __  320  2.8  2,792  _+  130  5.5 
0.01  641  _+  84  1.4  22,224  +__ 3,513  13.6  3,497  _+  210  6.9 
0.1  1,589  _+  133  3.4  14,865  +-  2,366  9.1  5,671  -+  269  11.2 
1.0  1,640  _+  179  3.5  14,732  +-  2,167  9.0  9,091  -+  74  17.9 
10.0  190  _+  27  0.4  96  -+  19  0.04  2,454  _+  147  4.8 
None  470  _+  45  -  1,633  _+  320  -  508  -+  60 
Heat  inactivated,  573  _+  67  -  1,700  _+  433  -  330  -+  51 
0.1  mg/ml 
D2V only, 1.0 mg/  26  _+  4  23  -  5  13  _+  2 
ml 
Results  of  single  representative  experiments  are  shown. 
*  Average of  mean plaque  counts  on days  2-5  culture  _+ standard  error  of  mean. 
PFU enzyme-treated/nontreated  PBL cultures. 
TABLE  VI 
Replication of D2 V in PBL Cultures from Eight Human Donors 
Incubated for Varying Periods Before Addition of D2V Plus D4 
Days in  culture  be-  Total  leuko-  fore  addition  of  D2V 
and aD4  cyte  assays 
Mean PFU/10  s  PBL - SE* 
D2V and aD4  D2V only 
0  21  4,487  _+  850  125  -+  6 
1  24  11,025  -  3,425  76  _+  4 
2  24  6,493  -+  2,717  111  -+  5 
3  20  1,838  _+  978  176  -+  7 
4  24  1,243  _+ 424  185  _+ 8 
*  Mean plaque  count  on days  2-4 of  culture  after  inoculation  _+ one 
standard  error  of  mean. 
dilution of i:I0  for 30 min at 37°C, cells  washed three times, counted, resus- 
pended, incubated, and assayed. Control cells  were not washed. Virus yields 
from PBL exposed to D2V for short periods were expressed as a ratio  of  control 
titers.  Virus content of  cells  cultured for 3-5 days is shown in Table VII. After 
10-15 rain incubation, comparatively little  virus could be removed from PBL by 
washing. A  significant fraction of  D2V was still  accessible to neutralization by 
specific  antibody through 30 rain of  incubation. D2V internalization was essen- 
tially  complete at 60-90 rain. The kinetics of  internalization of  D2V  in human 
PBL  are similar to those in monkey PBL. 
MOI.  The effect  of  virus dose on the kinetics of  replication and the threshold 
of infectivity  of PBL  was measured in human  and monkey  PBL. Serial 1-fold 
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TABLZ VII 
Kinetics of Internalization of D2V Plus aD4 in Rhesus PBL 
Method 
PFU days 3-5 washed/nonwashed PBL 
Exp.  Time 
no.  (min)  ...  5  10  15  30  60  90  120 
Wash x  3  1  ND  ND  ND  ND  1.0  ND  ND 
2  0.4  0.8  ND  1.0  1.0  ND  ND 
3  ND  ND  0.8  1.0  1.0  ND  1.0 
Wash x  1  1  0.0  0.1  ND  0.1  0.3  ND  1.0 
Anti-D2, 37°C ×  30min  2  0.1  0.1  0.2  0.4  0.7  1.0  ND 
Wash ×  3  3  ND  ND  0.3  0.5  0.8  ND  1.0 
Virus-antibody  added  to  PBL  for  progressively  longer  times,  then  leukocytes  are  washed  or 
incubated with anti-dengue 2 before culture. 
~b 
~(  0,Ol 
EXPERIMENT  I  EXPERIMENT  2 
I.  f. 
0,1  0,1 
IO-y  A 
o.o. 
DAY OF  CULTURE  DAY OF  CULTURE 
FIG.  5.  Kinetics of dengue 2 replication in relation to infecting visas dose  in two experi- 
ments. Mean PFU per 10  6  mononuclear PBL are shown for each  dose  on days 2-6 of culture. 
aD4 concentration constant in each  culture vessel. 
tration of antibody. Virus replication measured in two separate  experiments 
with  monkey PBL  is  shown  in  Fig.  5.  These  results  are  illustrative of the 
variation in D2V replication observed in different PBL donors. In exp. 1 compar- 
atively little difference was observed in virus yield or in the day of peak virus 
production over a ratio of virus:PBL of 10-1-10 -3. In exp. 2, dose-related differ- 
ences in virus yield were somewhat larger. In both experiments, a virus: PBL 
ratio of 10 -5 (an inoculated dose of approximately 100 PFU) was at the threshold 
of infection. With decreasing virus inocula there was retardation in the day of 
peak virus titer. 
Discussion 
In a large series of experiments performed under relatively basal conditions, 
D2V complexed with antibody entered and replicated in mononuclear leukocytes 
with high relative efficiency but  in the  absence of antibody did  so  at lower 
efficiency. Anti-dengue serums prepared  in several mammalian species  were 
equally efficient in mediating D2V infection. An Fc terminus was a requirement 
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treatment with several proteases. In the absence of C, infection was mediated by 
IgG but not IgM.  The kinetics  of internalization  of virus-antibody complexes 
was temporally similar to the kinetics of phagocytosis by mononuclear phago- 
cytes (32).  These  observations are  compatible  with the  data  described in the 
companion  paper  which  identify  the  antibody-dependent  dengue-permissive 
primate leukocyte as a  mononuclear phagocyte (21). 
We have shown that D2V infection of primate mononuclear phagocytes can be 
mediated by both homotypic and heterotypic anti-dengue IgG. Little is known of 
the molecular and  cellular  events which result in infection of a  mononuclear 
phagocyte rather  than  destruction  of virus.  Before this  study,  a  reasonable 
speculation would have been that strong interactions  between virus and anti- 
body might be lethal,  while weak interactions  might be capable of promoting 
immune phagocytosis, but the high rate of disassociation of the complex results 
in infection of the cell. We report for the first time the existence of an antibody 
subpopulation  which  appears  to  have  as  its  sole  measureable  function  the 
enhancement  of viral  infection in mononuclear phagocytes.  Two D2V-infected 
monkeys produced large  quantities  of infection-enhancing  IgG in serums  ob- 
tained 14 days postinfection. These fractions had no detectable HI or neutraliz- 
ing activity against  D2V.  The IgG subtype of this enhancing  IgG has not yet 
been determined.  It will be important to learn whether separate populations of 
IgG are active in the neutralization  and enhancement  phenomena. 
The  remarkable  ability  of very  low  concentrations  of anti-dengue  IgG  to 
promote dengue infection of mononuclear phagocytes is reminiscent of a similar 
sensitivity of leukocytes to the  antibody-dependent  cell-mediated  cytotoxicity 
phenomenon (33).  In most of our experiments the D to leukocyte ratio was less 
than  1. In experiments in which anti-dengue was diluted to 500-fold above the 
neutralization  end point,  it seems reasonable to conclude that  a  single virus- 
antibody complex may suffice to initiate infection. 
Enhancing  antibody does not attach  to mononuclear  phagocytes before the 
formation of immune complexes. This experiment thus did not provide insight 
into the nature of the D receptor on the surface of dengue-permissive leukocytes 
obtained from immune  donors.  It has  been speculated that  this  receptor is  a 
cytophilic  antibody  (15).  This  speculation  receives support  from  unpublished 
observations showing that silica treatment  of dengue-immune  PBL ablates in 
vitro  dengue  infection.  This  identifies  the  permissive  cell  as  a  mononuclear 
phagocyte,  a  cell frequently associated with cytophilic  antibody.  It will be of 
interest to determine if the dengue cell-associated receptor is an antibody and if 
so to identify the immunoglobulin type. 
The biological implications of in vitro antibody-mediated dengue infection of 
mononuclear  phagocytes  require  comment.  Severe  dengue  disease  occurs  in 
infants,  a  majority of whom are 6- to  10-mo-old. There  is evidence that these 
infants develop DSS during a primary dengue infection (6). In an age-stratified 
serological  study in  Bangkok it  was shown that  over 90%  of women of child- 
bearing age are immune to one or more D types (8). Thus,  most Bangkok-born 
infants acquire dengue antibody at birth.  By 6-10 mo, it is likely that maternal 
anti-dengue  IgG has waned to below the protective threshold.  But, as demon- 
strated in this study, antibodies at nonprotective concentrations  may be infec- 
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during the 1st yr of life resembles the "prozone" in the in vitro antibody infection 
enhancement  system.  When  homotypic  antibody  was  used,  neutralization  of 
virus occurred  with high  concentrations  of antibody  (protection  of the  young 
infant)  and  enhancement  of virus  infection  at  low  concentrations  (infection 
enhancement  in the older infant). 
When  studies  were done using  PBL from different individuals  or from the 
same individual bled repeatedly, the variation in the amount of virus replicated 
was notable. Separately, we have shown that virus production in vitro is related 
directly to the number of cells infected (21). Since in each of our experiments the 
concentrations  of infecting  virus  and  antibody  were held  constant,  the  most 
plausible  explanation  for variation  in  virus production  is  a  variation  in  the 
number of cells available to support dengue infection. The number of circulating 
permissive cells might vary between different persons and in individuals  seri- 
ally studied. The identity of the small fraction of mononuclear phagocytes which 
are  permissive  to dengue  infection  receives further  comment  elsewhere  (21). 
Individual variation in the size of a leukocyte population which can be rendered 
permissive by antibody might be related to the observation that  only a  small 
minority of persons undergoing secondary dengue infections develop DSS (IlL 
Regulation of the  size of mononuclear  phagocyte populations  is incompletely 
understood,  but  genetic,  hormonal,  and  nutritional  factors  and  preceding  or 
accompanying infections may be important.  The hypothesis that the permissive 
monocyte population varies according to the severity of dengue disease could be 
tested directly in man. We propose that the concentration of dengue-permissive 
PBL in patients  with secondary dengue  infections be compared in a  matched 
series of children with severe and mild disease. 
Studies should also be initiated on the role of biologically active molecules in 
regulating  the penetration,  synthesis,  and release of dengue viruses from in- 
fected mononuclear phagocytes. Epidemiological and autopsy studies have dem- 
onstrated that secondary dengue infections are more severe in girls than in boys 
(6, 34). This anomalous response to infectious disease might be explained by our 
results which relate infection of mononuclear phagocytes to the phenomenon of 
immune phagocytosis plus the observation of Vernon-Roberts who showed that 
some steroid hormones, including progesterone, increase phagocytosis by mono- 
nuclear phagocytes, in vivo (35). 
The identification of the mononuclear phagocyte as a host for dengue replica- 
tion  in  vitro,  and  the  demonstration  of a  mechanism  by which  antibody can 
regulate dengue infection of these cells serves to focus attention on the disease- 
producing  consequences of infection in this  cell system.  Recently it has been 
shown that various stimuli to mononuclear phagocytes results in the release of 
lysosomal  enzymes  (36).  Recently it  has  been  shown  that  C3a  and  C3b  can 
release lysosomal hydrolases from guinea pig macrophages (36). Macrophage as 
well as granulocyte lysosomal enzymes can cleave C3 to C3b (37, 38). Activated 
C3b with factor B  functions as a  proteinase,  cleaving further  C3 to C3b (39). 
Thus,  through  a  positive  feedback  mechanism  macrophages  are  potentially 
powerful activators of C via the alternative pathway. It is not yet established 
that  D  infection  of human  mononuclear  phagocytes  can  result  in  release  of 
lysosomal enzymes or other C-activating factors.  Viral  infections in other cell 
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dengue infection of mononuclear phagocytes results in C activation, the degree 
of activation  should  correlate  with  the  number  of mononuclear  phagocytes 
infected and render it unnecessary to invoke the production of virus-antibody 
complexes to  explain  C  consumption.  Such  an  hypothesis  would be  more  in 
accord with conditions  under  which  DSS occurs in  primarily  infected infants 
(very low levels of residual maternal anti-dengue IgG) or with the shock and C 
activation recently described in primarily infected children older than 1 yr (42). 
Indeed,  vasoactive  or  hemorrhagenic  compounds  whose  existence  is  as  yet 
unsuspected,  may  be  released  either  as  a  result  of virus  infection  or  when 
infected  mononuclear  phagocytes  are  under  immunological  attack.  We  are 
actively studying these interesting possibilities. 
Summary 
Cultured  mononuclear  peripheral  blood leukocytes (PBL) from nonimmune 
human beings and monkeys are nonpermissive to dengue 2 virus (D2V) infection 
at  multiplicities  of infection  of 0.001-0.1,  but become  permissive  when  non- 
neutralizing  dengue antibody is added to medium.  D2V infection occurred in 
PBL prepared from anti-coagulated but not from defibrinated plasma. Infection 
enhancement was produced by multiple lots of heterotypic anti-dengue raised in 
several mammalian  species.  Homotypic anti-dengue  neutralized  D2V at  high 
concentrations but enhanced at low concentrations;  enhancement  end point in 
one serum  was  1:320,000.  The infection-enhancing  factor was a  noncytophilic 
antibody of the IgG class.  D2V infection occurred in the absence of heat-labile 
complement components but did not occur when complexes were prepared with 
anti-dengue F(ab)2. Treatment of PBL with several proteases increased permis- 
siveness to D2V infection by immune  complexes but not by virus alone.  Two 
rhesus monkey serums collected 14 days after D2V infection contained an IgG 
antibody with high-titered  enhancing  activity but with no hemagglutination- 
inhibition  or neutralizing  activity.  Virus-antibody complexes are irreversibly 
attached to PBL within 15 min and completely internalized in 60 min. There was 
considerable variation in cellular infection in different experiments,  however, 
maximum virus yields usually exceeded 1,000 plaque-forming units per 1 ×  106 
PBL occurring between 2 and  4 days in culture.  In  vitro  antibody-dependent 
infection of PBL provides a possible model for study of pathogenetic mechanisms 
in infants  with dengue shock syndrome who passively acquire maternal  anti- 
dengue IgG. 
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